NEW YORK (GenomeWeb) – Entasis Therapeutics, a spinoff of AstraZeneca, has signed an agreement with BioMérieux to incorporate BioFire FilmArray diagnostic tests into upcoming clinical trials. The multiplex pneumonia panel will be used in trials for a drug to combat carbapenem-resistant A. baumannii infections.

Terms of the deal were not disclosed. Under the agreement, the BioFire FilmArray Pneumonia panel and instruments will be used in the global Phase III trial beginning in Q1 2019 to optimize enrollment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.